Abstract：
UNASSIGNED: Granuloma formation is an uncommon and persistent skin inflammatory condition caused by the injection of dermal fillers. The exact cause of this reaction is not well understood, but it may be associated with irritating components or abnormal immune function. Treating granulomas can be difficult. However, recent research has shown that Janus kinase (JAK) inhibitors hold promise as a potential therapy for refractory granulomatous diseases.
UNASSIGNED: The aim was to evaluate the efficacy and safety of tofacitinib as a treatment for granulomas secondary to filler injection and the possible mechanisms were discussed and summarized.
UNASSIGNED: This study focuses on three cases of patients who experienced granuloma formation after receiving filler injections and were subsequently treated with tofacitinib. The efficacy and safety of the treatment were evaluated using parameters such as photographs and monitoring for any adverse reactions. In addition, a literature review was conducted to explore the underlying mechanisms and potential effects of tofacitinib.
UNASSIGNED: All three cases recovered from swelling and nodules without side effects through the off-label use of oral tofacitinib. Existing data review reveals some approaches for cutaneous granulomatous disorders like inhibiting macrophage activation and downregulation of the JAK-STAT pathway.
UNASSIGNED: This report emphasizes the effectiveness of JAK inhibitors in treating granulomas caused by filler injections. Recent advancements in understanding the underlying mechanisms of granulomatous reactions have paved the way for JAK inhibitors to be regarded as a promising treatment choice. However, further research is necessary to fully assess the safety and long-term effectiveness of using tofacitinib for granuloma treatment.
UNASSIGNED: The aim was to evaluate the efficacy and safety of tofacitinib as a treatment for granulomas secondary to filler injection and the possible mechanisms were discussed and summarized.
UNASSIGNED: This study focuses on three cases of patients who experienced granuloma formation after receiving filler injections and were subsequently treated with tofacitinib. The efficacy and safety of the treatment were evaluated using parameters such as photographs and monitoring for any adverse reactions. In addition, a literature review was conducted to explore the underlying mechanisms and potential effects of tofacitinib.
UNASSIGNED: All three cases recovered from swelling and nodules without side effects through the off-label use of oral tofacitinib. Existing data review reveals some approaches for cutaneous granulomatous disorders like inhibiting macrophage activation and downregulation of the JAK-STAT pathway.
UNASSIGNED: This report emphasizes the effectiveness of JAK inhibitors in treating granulomas caused by filler injections. Recent advancements in understanding the underlying mechanisms of granulomatous reactions have paved the way for JAK inhibitors to be regarded as a promising treatment choice. However, further research is necessary to fully assess the safety and long-term effectiveness of using tofacitinib for granuloma treatment.
摘要：
■肉芽肿形成是由皮肤填充剂的注射引起的罕见且持续的皮肤炎症状况。这种反应的确切原因尚不清楚，但它可能与刺激成分或免疫功能异常有关。治疗肉芽肿可能很困难。然而,最近的研究表明，Janus激酶（JAK）抑制剂有望成为难治性肉芽肿疾病的潜在治疗方法。
■目的是评估托法替尼治疗填充剂注射继发肉芽肿的疗效和安全性，并讨论和总结可能的机制。
■本研究的重点是3例接受填充剂注射后出现肉芽肿形成并随后接受托法替尼治疗的患者。使用诸如照片和监测任何不良反应的参数来评估治疗的有效性和安全性。此外,本研究进行了文献综述,以探讨托法替尼的潜在作用和潜在作用.
■所有三例病例均通过超标签使用口服托法替尼，从肿胀和结节中恢复，无副作用。现有的数据综述揭示了一些治疗皮肤肉芽肿性疾病的方法，如抑制巨噬细胞活化和下调JAK-STAT通路。
■本报告强调了JAK抑制剂在治疗由填充剂注射引起的肉芽肿中的有效性。在了解肉芽肿反应的潜在机制方面的最新进展为JAK抑制剂被视为有希望的治疗选择铺平了道路。然而,需要进一步的研究来全面评估托法替尼治疗肉芽肿的安全性和长期有效性.
■目的是评估托法替尼治疗填充剂注射继发肉芽肿的疗效和安全性，并讨论和总结可能的机制。
■本研究的重点是3例接受填充剂注射后出现肉芽肿形成并随后接受托法替尼治疗的患者。使用诸如照片和监测任何不良反应的参数来评估治疗的有效性和安全性。此外,本研究进行了文献综述,以探讨托法替尼的潜在作用和潜在作用.
■所有三例病例均通过超标签使用口服托法替尼，从肿胀和结节中恢复，无副作用。现有的数据综述揭示了一些治疗皮肤肉芽肿性疾病的方法，如抑制巨噬细胞活化和下调JAK-STAT通路。
■本报告强调了JAK抑制剂在治疗由填充剂注射引起的肉芽肿中的有效性。在了解肉芽肿反应的潜在机制方面的最新进展为JAK抑制剂被视为有希望的治疗选择铺平了道路。然而,需要进一步的研究来全面评估托法替尼治疗肉芽肿的安全性和长期有效性.
